Minamiguchi K, Kitazato K T, Sasaki E, Nagase H, Kitazato K
Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Thromb Haemost. 1997 Jun;77(6):1148-53.
We studied the use of depolymerized holothurian glycosaminoglycan (DHG) as an anticoagulant in experimental beagle-dog hemodialysis using a hollow-fiber dialyzer compared to that using unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and nafamostat mesilate (FUT). Effectiveness was based on 5 h hemodialysis and no marked clot deposition in the extracorporeal circuit. At effective doses, UFH and LMWH significantly prolonged template bleeding time, in sharp contrast to FUT and DHG, which scarcely prolonged bleeding time during hemodialysis. DHG prolonged activated partial thromboplastin time (APTT) about 6 times that of normal plasma and prolonged thrombin clotting time (TCT) markedly; FUT showed marked APTT prolongation but hardly prolonged TCT in the hemodialysis circuit at the effective dose. The anticoagulant profile of DHG thus differs completely from that of FUT. These results suggest that DHG may be useful as anticoagulant for hemodialysis with low hemorrhagic risk.
我们研究了在使用中空纤维透析器的实验性比格犬血液透析中，与使用普通肝素（UFH）、低分子量肝素（LMWH）和甲磺酸萘莫司他（FUT）相比，解聚海参糖胺聚糖（DHG）作为抗凝剂的情况。有效性基于5小时的血液透析以及体外循环中无明显的血栓沉积。在有效剂量下，UFH和LMWH显著延长了模板出血时间，这与FUT和DHG形成鲜明对比，后者在血液透析过程中几乎不延长出血时间。DHG使活化部分凝血活酶时间（APTT）延长至正常血浆的约6倍，并显著延长凝血酶凝血时间（TCT）；在有效剂量下，FUT在血液透析回路中显示出明显的APTT延长，但几乎不延长TCT。因此，DHG的抗凝特性与FUT完全不同。这些结果表明，DHG可能作为出血风险低的血液透析抗凝剂有用。
